Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma

Surgical Oncology

Volumn 25, Issue 1, 2016, Pages 24-29

  Hirokawa, Fumitoshi ^a   Hayashi, Michihiro ^a   Asakuma, Mitsuhiro ^a   Shimizu, Tetsunosuke ^a   Inoue, Yoshihiro ^a   Uchiyama, Kazuhisa ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Early recurrence; Hepatocellular carcinoma; ICGR15; Indocyanine green retention rate at 15 min; Microvascular invasion; Treatment strategy

Indexed keywords

INDOCYANINE GREEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROVASCULARIZATION; MULTIPLE CANCER; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME; ADVERSE EFFECTS; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS; ETIOLOGY; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; INDOCYANINE GREEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84960392992     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2015.12.002     Document Type: Article

References (31)

1. M. Hayashi, T. Shimizu, F. Hirokawa, and et al. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma Am. Surg. 77 2011 572 578
2. X. Lu, H. Zhao, H. Yang, and et al. A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy J. Surg. Oncol. 100 2009 488 493
3. J.H. Park, K.C. Koh, M.S. Choi, and et al. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma Am. J. Surg. 192 2006 29 33
4. S.A. Shah, P.D. Greig, S. Gallinger, and et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes J. Am. Coll. Surg. 202 2006 275 283
5. M. Shimada, K. Takenaka, T. Gion, and et al. Prognosis of recurrent hepatocellular carcinoma: A 10-year surgical experience in Japan Gastroenterology 111 1996 720 726
6. M. Makuuchi, T. Kosuge, T. Takayama, and et al. Surgery for small liver cancers Semin. Surg. Oncol. 9 1993 298 304
7. F. Hirokawa, M. Hayashi, Y. Miyamoto, and et al. A novel method using the VIO soft-coagulation system for liver resection Surgery 149 2011 438 444
8. M. Rodriguez-Peralvarez, T.V. Luong, L. Andreana, and et al. A systematic review of microvascular invasion in hepatocellular carcinoma: Diagnostic and prognostic variability Ann. Surg. Oncol. 20 2013 325 339
9. H. Imamura, Y. Matsuyama, E. Tanaka, and et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy J. Hepatol. 38 2003 200 207
10. Y. Yamamoto, H. Ikoma, R. Morimura, and et al. Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy World J. Gastroenterol. 21 2015 1207 1215
11. T. Reya, S.J. Morrison, M.F. Clarke, and I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111
12. L. Fan, F. He, H. Liu, and et al. CD133: A potential indicator for differentiation and prognosis of human cholangiocarcinoma BMC Cancer 11 2011 320
13. S. Ma, K.W. Chan, L. Hu, and et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells Gastroenterology 132 2007 2542 2556
14. S. Ma, T.K. Lee, B.J. Zheng, and et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway Oncogene 27 2008 1749 1758
15. Z.F. Yang, D.W. Ho, M.N. Ng, and et al. Significance of CD90+ cancer stem cells in human liver cancer Cancer Cell 13 2008 153 166
16. K. Endo, and T. Terada Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: Relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival J. Hepatol. 32 2000 78 84
17. S.T. Fan, Z.F. Yang, D.W. Ho, and et al. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: A prospective study Ann. Surg. 254 2011 569 576
18. S. Eguchi, M. Takatsuki, M. Hidaka, and et al. Predictor for histological microvascular invasion of hepatocellular carcinoma: A lesson from 229 consecutive cases of curative liver resection World J. Surg. 34 2010 1034 1038
19. R.T. Poon, S.T. Fan, I.O. Ng, and et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma Cancer 89 2000 500 507
20. K. Ikeda, Y. Arase, S. Saitoh, and et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer Hepatology 32 2000 228 232
21. B. Damdinsuren, H. Nagano, M. Sakon, and et al. Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs Ann. Surg. Oncol. 10 2003 1184 1190
22. S. Kubo, S. Nishiguchi, K. Hirohashi, and et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial Ann. Intern. Med. 134 2001 963 967
23. Y.C. Shen, C. Hsu, L.T. Chen, and et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach J. Hepatol. 52 2010 889 894
24. Y. Muto, H. Moriwaki, M. Ninomiya, and et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group N. Engl. J. Med. 334 1996 1561 1567
25. E. Boucher, S. Corbinais, Y. Rolland, and et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma Hepatology 38 2003 1237 1241
26. M. Tabone, L. Vigano, A. Ferrero, and et al. Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis Eur. J. Surg. Oncol. 33 2007 61 66
27. T. Takayama, T. Sekine, M. Makuuchi, and et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial Lancet 356 2000 802 807
28. A.J. Davis, and J.F. Tannock Repopulation of tumour cells between cycles of chemotherapy: A neglected factor Lancet Oncol. 1 2000 86 93
29. Y. Xia, Y. Qiu, J. Li, and et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: A randomized controlled trial Ann. Surg. Oncol. 17 2010 3137 3144
30. Y. Nakashima, O. Nakashima, M. Tanaka, and et al. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type Hepatol. Res. 26 2003 142 147
31. M. Shi, R.P. Guo, X.J. Lin, and et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: A prospective randomized trial Ann. Surg. 245 2007 36 43